Stock Report

GlaxoSmithKline Pharmaceuticals Ltd announces Q4, FY26 results

Posted On : 2026-05-14 11:03:44( TIMEZONE : IST )

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) today announced its financial results for the fourth quarter and full year ended 31st March 2026. The Company continued its trajectory of profitable growth and margin expansion. This performance was driven by pricing measures, focused investments in innovative therapies, improved field force productivity, AI-led optimisation and disciplined cost management.

The Company reported full year revenue of INR 3790 crores, a growth of 2%. Profit After Tax (PAT) increased by 10% to INR 1012 crores, while EBITDA margins expanded by 290 basis points (bps) to 34%.

For the quarter ending 31st March 2026, the Company reported revenue of INR 989 crores and PAT of INR 275 crores while EBITDA margins improved by 90 bps to 35%.

As reported previously, supply chain disruptions during the year constrained the availability of certain key products leading to a material impact on topline growth. These challenges have accelerated the Company's efforts to strengthen supply chain resilience through enhanced contingency planning, diversified sourcing and improved end-to-end visibility to ensure business continuity.

Portfolio Performance Highlights

The General Medicines portfolio delivered competitive performance during the quarter, with the top 4 promoted brands growing ahead of the market (EI* >100; Source: IQVIA). Key promoted brands such as Augmentin, Calpol and T-Bact continued to reinforce their leadership positions in their respective categories while the tail-end distributed portfolio saw significant headwinds.

The Vaccines business grew on strong demand and continued leadership in the self-pay private paediatric vaccines market. Shingrix (Recombinant Herpes Zoster Vaccine, Adjuvanted) achieved critical mass as increasing awareness of preventive healthcare and adult immunisation translated into positive outcomes from in-clinic conversations.

The Oncology business, led by specialised therapies Jemperli (dostarlimab) and Zejula (niraparib), is tracking strongly. A key milestone this year was Jemperli's first-line approval by Indian regulators for primary advanced and recurrent endometrial cancer, leading to a significant expansion of the eligible patient population. This has laid the foundations for patient-centric and sustainable growth in Oncology.

Commenting on the full-year results, Mr. Bhushan Akshikar, Managing Director, GSK India, said: "The strong delivery of our Oncology portfolio signals a key inflection point in GSK India's journey to evolve into an innovation-led company, focused on areas of high unmet medical need. Our progress is underpinned by scientific rigour, disciplined execution and an unwavering commitment to our patients in India. Building on this momentum, we will continue to invest in innovative, high-growth therapy areas to make a positive impact at scale. Our ambition is driven by a sharp focus on topline growth and sustainable profitability."

The Company has received market authorisation in India for Blenrep (belantamab mafodotin), an anti-BCMA ADC** therapy indicated for relapsed or refractory multiple myeloma in adults. Multiple myeloma is the third most common blood cancer globally, with approximately 180,000 new cases a year.1 Launch plans will be announced at an appropriate time.

GlaxoSmithKline Pharmaceuticals Limited has recommended a final dividend of Rs.57/- per equity share on face value of Rs.10 each for the year ended 31st March 2026, subject to approval of members at 101 st Annual General Meeting. The Company has fixed Friday, 29th May 2026, as the Record Date for determining entitlement of members to final dividend for the financial year ended 31st March,2026. If the final dividend as recommended by the Board of Directors is approved at the AGM, payment of such dividend, subject to deduction of tax at source, will be made on and after Wednesday, 1st July 2026.

Shares of GlaxoSmithKline Pharmaceuticals Limited was last trading in BSE at Rs. 2406.85 as compared to the previous close of Rs. 2448.10. The total number of shares traded during the day was 10967 in over 1022 trades.

The stock hit an intraday high of Rs. 2493.00 and intraday low of 2386.35. The net turnover during the day was Rs. 26781784.00.